Weight loss Novo Nordisk - Search News

Novo Nordisk Stock Jumps

Barron's on MSN · 2h

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns.

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Fortune on MSN · 2h

As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs

Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.

Wall Street Journal on MSN · 7h

Novo Nordisk’s Wegovy Drug Sales Miss Expectations

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year.

4h

Lilly needs a plan to spur weight-loss drug sales, investors say

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

5d

Novo Nordisk Shares Have a Long Road Back from 40% Slump

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

5d

Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results